Organizer: Yumie RHEE (Yonsei University)
In the COVID-19 era, it also had a significant impact on the endocrine systems. Prof. Juliana Chan (The Chinese University of Hong Kong and Prince of Wales Hospital, Shatin, Hong Kong, China) will present the evidence on the devastating impact of COVID-19 on people with diabetes. People with type 1 diabetes had an almost 3-fold risk of death, and those with type 2 diabetes had an almost 2 times higher risk of death due to COVID-19 than those without diabetes. There are multiple affecting risk factors in diabetes patients. Prof Chan says: "SARS-CoV-2 may damage pancreatic beta-cells, the only insulin-secreting cells. As such, COVID-19 may precipitate diabetes in people with risk factors such as those with obesity, low socioeconomic status, and psychosocial stress." She will guide us through the importance of managing diabetes more actively in this devastating era. Surprisingly, bone and mineral metabolism were also affected by the COVID-19. Thus, Dr. Luigi Di Filippo(Vita-Salute San Raffaele University, Italy) will discuss the emerging osteo-metabolic phenotype of COVID-19. The osteo-metabolic phenotype is characterized by widespread acute hypocalcemia and chronic vitamin D deficiency, and a high prevalence of morphometric vertebral fractures. The ones who had this phenotype had higher mortality and morbidity with COVID-19 infection. Therefore, the importance of properly managing patients with COVID-19 with calcium and vitamin D replacement and avoiding discontinuation of anti-osteoporotic treatment will be discussed.

Organizer: Committee of Scientific Affairs
The first lecture of this session will be presented by Prof. Bipin Kumar SETI. Prof. Bipin Kumar SETI is a professor at Care Hospital in India and will give a lecture on the management of type 2 diabetes patients in the COVID-19 situation amid the recent rapid re-proliferation of COVID-19 in India.
Prof. Bo Yeon KIM will present the second lecture. Prof. Bo Yeon KIM is currently working in the Department of Endocrinology and Metabolism of Soon Chun Hyang University Bucheon Hospital and contributes herself to the development of research in endocrine diseases at home and abroad through active participation in various committees of the Korean Endocrine Society. In this lecture, she is going to give a lecture on CV safety through the big data analysis of Evogliptin which has been published recently in DOM. (Big data from the Health Insurance Review & Assessment Service in Korea)
The third lecture will be presented by Prof. Marcus HOMPESCH. Prof. Marcus HOMPESCH is CEO of Prosciento Clinical R&D (CRO) in California, USA, and has more than 25 years of experience in clinical R&D centered on metabolic diseases. Also, he has a lot of world-wide achievements in clinical development strategies and early research on medicines for diabetes and related metabolic diseases. In this lecture, he will give a lecture on the development process and phase 1a, 1b results of the future antidiabetic drug GPR-119 agonist ‘DA-1241’, which is being developed for the first in class.

Organizer: Committee of Scientific Affairs
This session will cover the latest trends in osteoporosis treatment under the theme of “Precision medicine in OP treatment: Should We Treat-to-Target or Target-to-Treat?”.
In aging society, interests in which drugs to start osteoporosis treatment and how to continue treatment to minimize osteoporotic fractures are increasing. This session will cover the recent global trend on osteoporosis treatment with denosumab and romosozumab by risk stratification and sequenced treatment approach. After the lectures by the three renowned speakers, in-depth discussions will be held with experts in Korea.

Organizer: Committee of Scientific Affairs
For this session, we invited three world-renowned speakers to investigate the latest trends in SGLT2 inhibitor and incretin therapy, which are showing excellent effects not only for blood sugar control, but also for cardiovascular and renal diseases among the diabetes drugs currently in use.

Professor Seven KAHN is a director at the University of Washington School of Medicine, Diabetes Research Center in Seattle, USA, has over 200 research papers, participated in large-scale clinical trials such as ADOPT, CAROLINA, DPP/DPPOS, GRADE, Look Ahead, NAVIGATOR, and RISE studies, and is actively conducting studies on the pathophysiology of diabetes and beta cells. In this SICEM Special session, he will give a lecture on how to protect beta cells of early-stage diabetes patients with SGLT2 inhibitor.

Professor David Cherney is currently working at the Department of Nephrology at the University of Toronto, Canada, and has participated in various clinical studies, including research on the pathophysiology of diabetic kidney disease and EPMA-Kidney and EUREKA studies. In this lecture, he is going to cover from the pathophysiology of diabetic kidney disease to the renal protection effect of SGLT2 inhibitor under the theme of how can SGLT2 inhibitor protect from the early stage of diabetic kidney disease.

Prof. Juris J. Meier is the director of Diabetology & GI Endocrinology department in Germany's St. Josef-Hospital of the Ruhr-Universität Bochum, and has published numerous research papers. He will provide a lecture focusing on the latest study findings on the mechanism, efficacy, and safety of a new incretin treatment drug.

Organizer: Mee Kyoung KIM (The Catholic University of Korea)
The 2020 Impact Factor of EnM, an international journal of the Korean Endocrine Society, was released as 4.01, and several excellent papers have been published. This session is an opportunity to listen to the lectures directly from the authors of the papers selected as the most interesting papers among the latest papers published in EnM.

1. Cushing Syndrome Associated Myopathy: It is Time for a Change
- Presented by Professor Martin REINCKE, President of the European Society of Endocrinology
- He will give lecture on the fact that myopathy is an important comorbidity that affects the quality of life of the patients with Cushing syndrome, and the latest study findings on the mechanism and treatment of myopathy related to Cushing syndrome.

2. Operationalizing Treat-to-Target for Osteoporosis
- Presented by Professor E. Michael LEWIECKI, Director of the New Mexico Clinical Research & Osteoporosis Center
- He will introduce the concept of treat-to-target in preparation for standard treatment (step therapy) in osteoporosis treatment, and explain that treat-to-target can demonstrate good treatment efficacy by establishing an individualized treatment plan even though the initial treatment cost is high.

3. Subclinical hypothyroidism: Prevalence, health impact, and treatment landscape
- Presented by Professor Hyeon Jeong JEONG, Department of Endocrinology, Dankook University
- She will give lecture on the domestic and international prevalence related to asymptomatic hypothyroidism, the importance of distinguishing between transient, reversible causes and persistent, progressive causes when treating patients with asymptomatic hypothyroidism, and the treatment guideline including other considerations.

Organizer: Committee of Scientific Affairs
The session is aiming to have patient-centered discussion on clinical importance of co-morbidity management, β-cell preservation and early combination therapy to achieve glycemic target in treating type 2 diabetes mellitus.

Organizer: Man-Ho CHOI (Korea Institute of Science and Technology)
Steroidogenesis is of fundamental importance to understanding endocrine disorders of fertility, hypertension, obesity and physiological homeostasis associated with HPA and HPG axes. The session provides metabolic insights in adrenal diseases, steroidogenic regulation with insulin signaling, and recent advances in 11-oxygenated androgen metabolism in various disorders.

Organizer: Committee of Scientific Affairs
Currently individualized treatment is strongly supported by the latest treatment guideline. This session address how can make optimal treatment strategies align with patients’ situations, particularly considering progressive disease of diabetes, and it will deliver how to delay insulin therapy with early oral combination treatment for better quality of life for patients.
3 speakers will share their scientific knowledge and experience based on evidence focused on Asian patients considering their characteristic.